Across TCGA pan-cancer cohorts, RPS20P15 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated RPS20P15 data layer.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RPS20P15 RNA is associated with better overall survival. In most high-consensus cancer types, elevated RPS20P15 expression acts as an unfavorable survival marker, although some lineages such as OV and COAD show a favorable association.
OV, MESO, and THCA are the cancer types where RPS20P15 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.